The independent source for health policy research, polling, and news.
301-320 of 478 results
Data and safety monitoring boards work under a cloak of secrecy meant to prevent undue influence by stakeholders, such as companies or the government. In the Trump era, some worry the anonymity could actually invite it.
The Trump administration is primed to approve a plan designed to help lower costs of some prescription drugs by allowing states to import them from Canada. The announcement could come before Election Day, and Florida appears to be in line to go first.
President Donald Trump this week issued a prescription drug pricing order unlikely to lower drug prices, and he contradicted comments by his director of the Centers for Disease Control and Prevention on the need for mask-wearing and predictions for vaccine availability. Meanwhile, scandals erupted at the CDC, the Centers for Medicare & Medicaid Services and the Food and Drug Administration. And the number of people without health insurance grew in 2019, reported the Census Bureau, even while the economy soared. Alice Miranda Ollstein of Politico, Tami Luhby of CNN and Sarah Karlin-Smith of the Pink Sheet join KHN鈥檚 Julie Rovner to discuss this and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
Republicans have all but abandoned the Affordable Care Act as a campaign cudgel, judging from their national convention, at least. Meanwhile, career scientists at the federal government鈥檚 preeminent health agencies 鈥 the Food and Drug Administration, the Centers for Disease Control and Prevention and the National Institutes of Health 鈥 are all coming under increasing political pressure as the pandemic drags on. Joanne Kenen of Politico, Mary Ellen McIntire of CQ Roll Call and Sarah Karlin-Smith of the Pink Sheet join KHN鈥檚 Julie Rovner to discuss this and more. Plus, Rovner interviews KHN鈥檚 Elizabeth Lawrence about the latest KHN-NPR 鈥淏ill of the Month鈥 installment.
About 60% of poll respondents are worried that federal regulators will rush to allow a vaccine because of political pressure. Opposition to getting a vaccine that might be authorized before the November election is strongest among Republicans.
The FDA, under pressure from the Trump administration, has authorized broader use of convalescent plasma for emergency treatment in COVID patients. But several major hospitals are resisting, saying they鈥檒l opt instead to use the scarce resource to complete a clinical trial.
President Donald Trump touted the Food and Drug Administration鈥檚 approval of this unproven COVID-19 treatment for emergency use. That set off reactions ranging from excitement and optimism to scientific concerns and criticism that the decision was politically motivated.
Experts say the administration鈥檚 approach with antigen tests could add cost and risk for the most vulnerable patients.
This statement is taken from a video in which a group of doctors air unproven conspiracy theories about the coronavirus. Dr. Immanuel's claims were among the most inaccurate. And, before it was removed from social media platforms, thee video was viewed millions of times. President Donald Trump retweeted it.
The FDA must approve any coronavirus vaccine before it鈥檚 widely distributed, but political pressure could cloud the decision.
President Donald Trump has, for now at least, become a realist on the extent of the COVID-19 crisis around the country, and he is urging Americans to socially distance and wear masks. Meanwhile, on Capitol Hill, Republicans facing a July 31 deadline are scrambling to come together on their version of the next COVID relief bill. Joanne Kenen of Politico, Margot Sanger-Katz of The New York Times and Tami Luhby of CNN join KHN鈥檚 Julie Rovner to discuss this and more. Also, Rovner interviews NPR鈥檚 Pam Fessler, author of the new book 鈥淐arville鈥檚 Cure,鈥 which traces the history of the United States鈥 only federal leprosarium.
The Food and Drug Administration released new 鈥渢emporary guidance鈥 for manufacturers facing supply chain shortages that allows them to make some ingredient substitutions without changing food labels. The pandemic had already made finding trusted foods difficult for some people with allergies. Now they're worrying about what's actually in their go-to products.
The pandemic has been marked by a significant amount of misinformation 鈥 some spread on purpose 鈥 that could prove deadly.
After the FDA issues a public warning about the test, one of its senior officials says point-of-care coronavirus tests can miss 20% of cases and still be considered useful. Public health experts are split.
If you鈥檝e been in a crowd 鈥 a protest or rally 鈥 experts have advice for figuring out whether you might have been exposed to the coronavirus, and where and when to get tested for it.
The Trump administration rolled back protections for transgender patients just days before the Supreme Court cemented LGBTQ rights under the Civil Rights Act. So, what now? Meanwhile, coronavirus politics reaches beyond health care settings. Anna Edney of Bloomberg News, Tami Luhby of CNN and Shefali Luthra of KHN join KHN鈥檚 Julie Rovner to discuss this and more. Also, for extra credit, the panelists recommend their favorite health stories of the week they think you should read, too.
Amid questions about the accuracy of the COVID-19 antibody tests flooding the market 鈥 and the usefulness of the results they provide 鈥 the FDA has belatedly stepped in to try to rein in the chaos.
Some communities considered community antibody testing as a way out of lockdown. But they've pulled back as they realized antibody testing is the Wild West in an oversight vacuum.
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don't have to.
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don't have to.
漏 2026 KFF